Jacob Sten Petersen has been Senior Vice President as Head of Global Nucleic Acid Therapies since 2023, responsible for RNAi modality and gene editing modality platform. He joined the Board of Directors of Novo Nordisk Pharmatech A/S in 2021.
Mr. Petersen joined Novo Nordisk in 2001 as CVP for Global Research Metabolic Diseases and Adjunct Professor. In 2006, he was awarded the Doctor of Medical Science (DMSc) degree from the medical faculty of Copenhagen University, Denmark, and from 2010-2022, he was a professor of biomedicine at the medical faculty of Copenhagen University.
Besides numerous presentations at international diabetes conferences, he has published approximately 70 papers in peer-reviewed journals, mainly on topics of diabetes prediction, prevention, and intervention but also on beta cell biology, physiology, and immunology.
